Emergent Biosolutions (NYSE:EBS) Downgraded by Wall Street Zen to “Buy”

Emergent Biosolutions (NYSE:EBS) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other analysts also recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Emergent Biosolutions in a report on Tuesday, December 16th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Emergent Biosolutions in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Emergent Biosolutions presently has an average rating of “Hold” and an average price target of $15.00.

Emergent Biosolutions Price Performance

Shares of EBS opened at $8.19 on Friday. The company has a current ratio of 5.76, a quick ratio of 3.15 and a debt-to-equity ratio of 1.14. The stock’s 50 day moving average is $11.68 and its two-hundred day moving average is $10.40. Emergent Biosolutions has a twelve month low of $4.02 and a twelve month high of $14.06. The firm has a market capitalization of $429.98 million, a PE ratio of 9.75 and a beta of 2.35.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of $0.11 by ($0.54). Emergent Biosolutions had a return on equity of 15.62% and a net margin of 7.08%.The company had revenue of $148.70 million for the quarter, compared to analysts’ expectations of $217.50 million. Research analysts anticipate that Emergent Biosolutions will post -0.63 earnings per share for the current year.

Insider Activity

In other news, Director Ronald Richard sold 21,984 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $11.97, for a total value of $263,148.48. Following the sale, the director directly owned 98,417 shares in the company, valued at $1,178,051.49. This represents a 18.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Emergent Biosolutions

Institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC grew its holdings in Emergent Biosolutions by 68.9% during the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after buying an additional 1,020,582 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Emergent Biosolutions by 108.9% in the second quarter. Geode Capital Management LLC now owns 1,278,998 shares of the biopharmaceutical company’s stock worth $8,162,000 after acquiring an additional 666,708 shares during the last quarter. Jain Global LLC purchased a new stake in shares of Emergent Biosolutions in the third quarter valued at $4,487,000. HRT Financial LP purchased a new position in Emergent Biosolutions in the 4th quarter valued at about $3,853,000. Finally, Dimensional Fund Advisors LP grew its stake in Emergent Biosolutions by 15.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,140,340 shares of the biopharmaceutical company’s stock worth $18,878,000 after acquiring an additional 291,308 shares during the period. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Key Stories Impacting Emergent Biosolutions

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Won multiyear Canadian contracts worth up to ~CAD 140 million, including >CAD 35M in orders expected in 2026, which adds near-term funded backlog and visibility for future revenue. Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada
• Positive Sentiment: Board authorized a new $50 million stock repurchase program (replacing the prior authorization); buybacks can support the share price and signal confidence from management. Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
• Positive Sentiment: Company highlights a return to profitability and ongoing turnaround progress, which could improve investor sentiment if execution continues. Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround
• Neutral Sentiment: Full Q4 prepared remarks, slide deck and presentation materials were filed — useful for digging into segment trends, contract timing and margin details but not a near-term catalyst by itself. Earnings Call Prepared Remarks Transcript Q4 Results – Earnings Call Presentation
• Neutral Sentiment: Local coverage and snapshots summarize the quarter and management commentary; useful background for investors reviewing call takeaways. Emergent Biosolutions: Q4 Earnings Snapshot
• Negative Sentiment: Q4 results missed expectations: EPS of ($0.43) vs. consensus $0.11 and revenue $148.7M vs. est. $217.5M — a clear earnings and top-line shortfall that weighed on the stock. Earnings Call Highlights: Strategic Gains Amid Revenue …
• Negative Sentiment: FY‑2026 revenue guidance was reset much lower to ~$720M–$760M versus street expectations near $1.2B; EPS guidance was not clearly reiterated in the release — the weak outlook is the primary driver of the share decline. Earnings Call Highlights: Strategic Gains Amid Revenue …

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.